Hairy Cell Leukemia - Pipeline Review, H2 2015 Is Released

From: IData Insights
Published: Tue Oct 31 2017

Hairy Cell Leukemia - Pipeline Review, H2 2015 Summary Global Markets Direct s, Hairy Cell Leukemia - Pipeline Review, H2 2015, provides an overview of the Hairy Cell Leukemias therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hairy Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hairy Cell Leukemia and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hairy Cell Leukemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hairy Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hairy Cell Leukemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hairy Cell Leukemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hairy Cell Leukemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Browse with TOC @
To Get Sample Copy of Report visit @
Table of Contents

Introduction 6

Global Markets Direct Report Coverage 6

Hairy Cell Leukemia Overview 7

Therapeutics Development 8

Pipeline Products for Hairy Cell Leukemia - Overview 8

Hairy Cell Leukemia - Therapeutics under Development by Companies 9

Hairy Cell Leukemia - Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Unknown Stage Products 13

Hairy Cell Leukemia - Products under Development by Companies 14

Hairy Cell Leukemia - Companies Involved in Therapeutics Development 15

AbbVie Inc. 15

Astellas Pharma Inc. 16

AstraZeneca Plc 17

Biogenomics Limited 18

F. Hoffmann-La Roche Ltd. 19

Inbiopro Solutions Pvt. Ltd. 20

Incyte Corporation 21

MedImmune, LLC 22

Novartis AG 23

Hairy Cell Leukemia - Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Combination Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

(dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

(INCB-039110 + INCB-040093) - Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

AGS-67E - Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

AZD-6738 - Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

IBPB-006IA - Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

ibrutinib - Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

INCB-39110 - Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

INCB-40093 - Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

INCB-50465 - Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

interferon alfa-2a - Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

interferon alfa-2b - Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

interferon alfa-2b - Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

moxetumomab pasudotox - Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

vemurafenib - Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Hairy Cell Leukemia - Recent Pipeline Updates 61

Hairy Cell Leukemia - Dormant Projects 88

Hairy Cell Leukemia - Discontinued Products 89

Hairy Cell Leukemia - Product Development Milestones 90

Featured News & Press Releases 90

May 16, 2013: AstraZeneca's MedImmune Enrolls First Patient In Phase III Leukemia Trial Of Moxetumomab Pasudotox 90

Appendix 91

Methodology 91

Coverage 91

Secondary Research 91

Primary Research 91

Expert Panel Validation 91

Contact Us 91

Disclaimer 92

Read More
About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.
iData Insights
Tel: 1-866-237-2965

About iData Insights
We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects
Company: IData Insights
Contact Name:
Contact Email:
Contact Phone: 18662372965

Visit website »